Pila Pharma AB (publ) (PILA.ST)
SEK 3.4
(-1.45%)
SEK 3.4
(-1.45%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.45 Million SEK | -22.34% |
| 2022 | 10.88 Million SEK | -65.78% |
| 2021 | 31.81 Million SEK | 492.67% |
| 2020 | 5.36 Million SEK | -32.42% |
| 2019 | 7.94 Million SEK | 8.57% |
| 2018 | 7.31 Million SEK | -2.72% |
| 2017 | 7.51 Million SEK | 482.82% |
| 2016 | 1.29 Million SEK | 232.73% |
| 2015 | 387.78 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.48 Million SEK | -46.93% |
| 2024 Q2 | 4.48 Million SEK | 0.0% |
| 2023 Q4 | 8.45 Million SEK | 109.44% |
| 2023 FY | 8.45 Million SEK | -22.34% |
| 2023 Q1 | 6.83 Million SEK | -37.26% |
| 2023 Q2 | 3.46 Million SEK | -49.33% |
| 2023 Q3 | 4.03 Million SEK | 16.64% |
| 2022 Q2 | 14.57 Million SEK | -32.03% |
| 2022 FY | 10.88 Million SEK | -65.78% |
| 2022 Q1 | 21.44 Million SEK | -32.57% |
| 2022 Q4 | 10.88 Million SEK | 25.18% |
| 2022 Q3 | 8.69 Million SEK | -40.35% |
| 2021 Q1 | 16.62 Million SEK | 209.75% |
| 2021 FY | 31.81 Million SEK | 492.67% |
| 2021 Q4 | 31.81 Million SEK | -15.07% |
| 2021 Q3 | 37.45 Million SEK | 263.06% |
| 2021 Q2 | 10.31 Million SEK | -37.95% |
| 2020 FY | 5.36 Million SEK | -32.42% |
| 2020 Q4 | 5.36 Million SEK | 0.0% |
| 2019 FY | 7.94 Million SEK | 8.57% |
| 2018 FY | 7.31 Million SEK | -2.72% |
| 2017 FY | 7.51 Million SEK | 482.82% |
| 2016 FY | 1.29 Million SEK | 232.73% |
| 2015 FY | 387.78 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| NextCell Pharma AB | 81.28 Million SEK | 89.599% |
| Biovica International AB (publ) | 131.4 Million SEK | 93.566% |
| Abliva AB (publ) | 87.49 Million SEK | 90.337% |
| Active Biotech AB (publ) | 44 Million SEK | 80.784% |
| Aptahem AB (publ) | 63.02 Million SEK | 86.585% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 92.862% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 99.396% |
| BioArctic AB (publ) | 1.18 Billion SEK | 99.287% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 86.396% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.555% |
| Cantargia AB (publ) | 223.71 Million SEK | 96.221% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | 43.137% |
| CombiGene AB (publ) | 120.61 Million SEK | 92.99% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 98.888% |
| Fluicell AB (publ) | 9.34 Million SEK | 9.475% |
| Genovis AB (publ.) | 288.85 Million SEK | 97.073% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 99.169% |
| Mendus AB (publ) | 755.95 Million SEK | 98.882% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 99.328% |
| LIDDS AB (publ) | 17.65 Million SEK | 52.11% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 79.849% |
| Saniona AB (publ) | 64.14 Million SEK | 86.819% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 84.043% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 86.445% |
| Xintela AB (publ) | 18.39 Million SEK | 54.036% |
| Amniotics AB (publ) | 26.08 Million SEK | 67.588% |
| Corline Biomedical AB | 100.1 Million SEK | 91.554% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 71.978% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 97.593% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 95.226% |
| Intervacc AB (publ) | 259.61 Million SEK | 96.743% |
| Kancera AB (publ) | 65.64 Million SEK | 87.12% |
| Lipum AB (publ) | 12.11 Million SEK | 30.182% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 74.838% |
| Nanologica AB (publ) | 77.42 Million SEK | 89.08% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 98.296% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 98.706% |
| AcouSort AB (publ) | 34.51 Million SEK | 75.502% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 96.104% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 89.256% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 96.967% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 57.811% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 98.895% |
| Simris Alg AB (publ) | 174.55 Million SEK | 95.156% |
| Ziccum AB (publ) | 14.97 Million SEK | 43.528% |
| SynAct Pharma AB | 228.01 Million SEK | 96.292% |
| OncoZenge AB (publ) | 20.34 Million SEK | 58.432% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.557% |
| 2cureX AB (publ) | 16.62 Million SEK | 49.143% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -39.131% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 93.986% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 61.042% |
| I-Tech AB | 152.44 Million SEK | 94.454% |
| Cyxone AB (publ) | 43.65 Million SEK | 80.632% |
| Biosergen AB | 7.2 Million SEK | -17.414% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 68.408% |
| Alzinova AB (publ) | 123.18 Million SEK | 93.137% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 96.453% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 90.079% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 90.29% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 70.342% |